Aptabio Therapeutics Stock Current Liabilities
| 293780 Stock | 7,200 60.00 0.84% |
AptaBio Therapeutics fundamentals help investors to digest information that contributes to AptaBio Therapeutics' financial success or failures. It also enables traders to predict the movement of AptaBio Stock. The fundamental analysis module provides a way to measure AptaBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AptaBio Therapeutics stock.
AptaBio |
AptaBio Therapeutics Company Current Liabilities Analysis
AptaBio Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, AptaBio Therapeutics has a Current Liabilities of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. This indicator is about the same for all Republic of Korea stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
AptaBio Fundamentals
| Return On Equity | -17.47 | |||
| Return On Asset | -0.0568 | |||
| Operating Margin | (17.13) % | |||
| Current Valuation | 794.49 B | |||
| Shares Outstanding | 10.88 M | |||
| Shares Owned By Insiders | 34.04 % | |||
| Shares Owned By Institutions | 3.46 % | |||
| Price To Sales | 926.14 X | |||
| Revenue | 223.68 M | |||
| Gross Profit | 336.97 M | |||
| EBITDA | (6.58 B) | |||
| Net Income | (10.69 B) | |||
| Cash And Equivalents | 6.57 B | |||
| Total Debt | 46.77 M | |||
| Cash Flow From Operations | (8.9 B) | |||
| Beta | 2.39 | |||
| Market Capitalization | 111.21 B | |||
| Total Asset | 64.91 B | |||
| Net Asset | 64.91 B |
About AptaBio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AptaBio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AptaBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AptaBio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in AptaBio Stock
AptaBio Therapeutics financial ratios help investors to determine whether AptaBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AptaBio with respect to the benefits of owning AptaBio Therapeutics security.